| Code | CSB-RA011663MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to benralizumab, targeting the interleukin-5 receptor alpha chain (IL5RA, also known as CD125). IL5RA forms part of the heterodimeric receptor complex for interleukin-5, a key cytokine that regulates the development, activation, and survival of eosinophils. The IL-5/IL5RA signaling pathway plays a critical role in eosinophil-mediated inflammation, making it central to the pathophysiology of severe eosinophilic asthma, chronic rhinosinusitis with nasal polyposis, hypereosinophilic syndrome, and eosinophilic granulomatosis with polyangiitis.
Benralizumab is an afucosylated humanized IgG1κ monoclonal antibody that binds to IL5RA on eosinophils and basophils, inducing antibody-dependent cell-mediated cytotoxicity (ADCC) and resulting in rapid depletion of these cell populations. This biosimilar antibody provides researchers with a valuable tool for investigating eosinophil biology, IL-5 signaling mechanisms, and eosinophilic inflammatory processes in various disease models. It supports studies examining therapeutic mechanisms and potential applications in allergic and inflammatory disorders.
There are currently no reviews for this product.